Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin effect on BMS-986278 PK
NCT03712540Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 8, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration up to 24 days and 2 more. Started Sep 2018; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT03712540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712540.